# APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery

> **NCT02166255** · PHASE1 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 17 (actual)

## Conditions studied

- Recurrent Melanoma
- Recurrent Pancreatic Cancer
- Recurrent Renal Cell Cancer
- Stage III Pancreatic Cancer
- Stage III Renal Cell Cancer
- Stage IIIA Melanoma
- Stage IIIB Melanoma
- Stage IIIC Melanoma
- Stage IV Melanoma
- Stage IV Pancreatic Cancer
- Stage IV Renal Cell Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **BIOLOGICAL:** siRNA-transfected peripheral blood mononuclear cells APN401
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT02166255
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2018-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02166255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02166255, "APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02166255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*